Results 31 to 40 of about 41,281 (176)
Background: Higher plasma tenofovir concentrations are associated with higher risks of renal and bone adverse events. The pharmacokinetic boosters ritonavir (RTV) and cobicistat (COBI) significantly increase plasma area under the curve (AUC ...
Andrew Hill +3 more
doaj +1 more source
Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval +6 more
wiley +1 more source
Ritonavir Has Reproductive Toxicity Depending on Disrupting PI3K/PDK1/AKT Signaling Pathway
Ritonavir (RTV) is an antiviral and a component of COVID-19 treatments. Moreover, RTV demonstrates anti-cancer effects by suppressing AKT. However, RTV has cytotoxicity and suppresses sperm functions by altering AKT activity.
Eun-Ju Jung +7 more
doaj +1 more source
Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen +14 more
wiley +1 more source
Nirmatrelvir/ritonavir is a novel drug combination authorized by the US Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19).
Yinhua Gong +4 more
doaj +1 more source
The control of crystal polymorphs is central to the design of pharmaceuticals and functional materials. Conventionally, crystal polymorph production has been controlled primarily by adjusting chemical and thermodynamic parameters.
Yoshio Kondo +4 more
doaj +1 more source
[english] Objective: To report on a case of retinal pigment epithelium (RPE) toxicity apparently associated with ritonavir.Methods: We describe a case of gradual-onset blurry vision in both eyes in a 30-year-old HIV-positive male on Highly-Active ...
Santos, Luisa +4 more
doaj +1 more source
Summary: Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/
Jon Salmanton-García +115 more
doaj +1 more source
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly ...
Clara Laffitte Redondo +12 more
wiley +1 more source
Marit Vermunt,1 Serena Marchetti,2 Jos Beijnen1,3,4 1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066, CX, the Netherlands; 2Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066,
Vermunt M, Marchetti S, Beijnen J
doaj

